1-[4-(1H-benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-[4-(1H-benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea
• 英文别名: 1-[4-(1H-benzoimidazol-2-yl)phenyl]-3-[4-1H-benzoimidazol-2-ylphenyl]urea；N,N'-Bis[4-(1H-benzimidazol-2-yl)phenyl]urea；1,3-bis-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea；1,3-bis[4-(1H-benzimidazol-2-yl)phenyl]urea
• 化学式: C₂₇H₂₀N₆O
• 分子量: 444.495
• InChiKey: BQLOPROPJDPFEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  98.5
• 氢给体数：
  4
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对氨基苯甲酸 在 盐酸 作用下， 以 水 为溶剂， 反应 0.07h， 生成 1-[4-(1H-benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea
  参考文献：
  名称：

  Molecular docking guided structure based design of symmetrical N,N′-disubstituted urea/thiourea as HIV-1 gp120–CD4 binding inhibitors

  摘要：

  Induced fit molecular docking studies were performed on BMS-806 derivatives reported as small molecule inhibitors of HIV-1 gp120-CD4 binding. Comprehensive study of protein-ligand interactions guided in identification and design of novel symmetrical N,N'-disubstituted urea and thiourea as HIV-1 gp120-CD4 binding inhibitors. These molecules were synthesized in aqueous medium using microwave irradiation. Synthesized molecules were screened for their inhibitory ability by HIV-1 gp120-CD4 capture enzyme-linked immunosorbent assay (ELISA). Designed compounds were found to inhibit HIV-1 gp120-CD4 binding in micromolar (0.013-0.247 mu M) concentrations. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.038

文献信息

• SYMMETRICAL 2-AMINOPHENYL-BENZAZOLYL-5-ACETATE COMPOUNDS AND THEIR USE AS ANTI-HEPARANASE
  申请人：Leadiant Biosciences SA

  公开号：EP3381907A1

  公开（公告）日：2018-10-03

  The present invention relates to symmetrical 2-aminophenyl-benzazolyl-5-acetate compounds of formula (I). Such compounds are endowed with an anti-heparanase activity. The present invention also relates to the use of such compounds as a medicament, in particular for the treatment of diseases and disorders associated with a heparanase activity, and to pharmaceutical compositions comprising the same.

  本发明涉及符合式(I)的对称2-氨基苯基-苯并咪唑-5-乙酸酯化合物。这些化合物具有抗肝素酶活性。本发明还涉及将这些化合物用作药物，特别是用于治疗与肝素酶活性相关的疾病和紊乱，并涉及包含这些化合物的药物组合物。
• SYMMETRICAL TRIS-ARYL-AMIDE DERIVATIVES AND THEIR USE AS ANTI-HEPARANASE
  申请人：Leadiant Biosciences SA

  公开号：EP3381898A1

  公开（公告）日：2018-10-03

  The present invention relates to tris-aryl-amide derivatives having an anti-heparanase activity, in particular it relates to ureido/thioureido/ether tris-aryl-amide derivatives of formula The invention also relates to the use of such compounds as a medicament, in particular for the treatment of diseases and disorders associated with heparanase activity, and to pharmaceutical compositions comprising the same.

  本发明涉及具有抗肝素酶活性的三芳基酰胺衍生物，特别涉及公式的脲/硫脲/醚三芳基酰胺衍生物。本发明还涉及将这种化合物用作药物的用途，特别是用于治疗与肝素酶活性相关的疾病和障碍，并且涉及包含这些化合物的制药组合物。
• [EN] (BENZIMIDAZOL-2-YL)-PHENYL-PHENYL-UREA COMPOUNDS AND METHODS FOR INHIBITING HEPARANASE ACTIVITY<br/>[FR] COMPOSES DE (BENZIMIDAZOL-2-YL)-PHENYL-PHENYL-UREE ET PROCEDES D'INHIBITION DE L'ACTIVITE DE L'HEPARANASE
  申请人：IMCLONE SYSTEMS INC

  公开号：WO2005042495A1

  公开（公告）日：2005-05-12

  The present invention encompasses heparanase inhibitors, particularly to certain (benzimidazol-2-yl)-phenyl-phenyl-urea derivatives that inhibit heparanase, pharmaceutical compositions that contain the compounds, methods for making the compounds, and methods of treating heparanase-dependent diseases and conditions in mammals by administering a therapeutically effective amount of the compounds to the mammals.

  本发明涉及抑制肝素酶的抑制剂，特别是某些（苯并咪唑-2-基）-苯基-苯基-脲衍生物，这些衍生物可以抑制肝素酶，以及包含这些化合物的制药组合物，制备这些化合物的方法，以及通过向哺乳动物施用治疗有效量的这些化合物来治疗肝素酶依赖性疾病和病况的方法。
• PREPARATION FOR PREVENTING OR AMELIORATING WRINKLES, TO BE TAKEN ORALLY, THROUGH INJECTION, OR THROUGH EXTERNAL APPLICATION TO SKIN, AND COSMETIC METHOD
  申请人：Shiseido Company, Ltd.

  公开号：EP2295028A1

  公开（公告）日：2011-03-16

  Wrinkles are improved by applying an oral preparation, injection preparation or external skin preparation having a substance that controls heparanase as an active ingredient thereof.

  口服制剂、注射制剂或外用护肤制剂的活性成分中含有控制肝素酶的物质，可以改善皱纹。
• HEPARANASE ACTIVITY INHIBITOR
  申请人：SHISEIDO CO., LTD.

  公开号：EP2484359A1

  公开（公告）日：2012-08-08

  A heparanase activity inhibitor comprising, as an active ingredient, a cyclic carboxamide derivative represented by formula (I): wherein n is an integer of 1 to 3, R1 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, X is -CH2- or a group represented by -N(R2)-, and R2 is hydrogen or a C1-6 hydrocarbon group optionally substituted with hydroxyl, or a salt thereof.

  一种肝素酶活性抑制剂，其活性成分包括由式（I）表示的环状羧酰胺衍生物： 其中 n 为 1 至 3 的整数，R1 为氢或任选被羟基取代的 C1-6 烃基，X 为 -CH2- 或由 -N(R2)- 代表的基团，R2 为氢或任选被羟基取代的 C1-6 烃基、 或其盐。